We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy

EP22456
Poster Title: HOMOGENEOUS ADCs BEARING TWO DIFFERENT PAYLOADS SHOW STRONG SYNERGY IN TUMOR KILLING
Submitted on 28 Oct 2014
Author(s): Lisha Allen, Yi Mi, Muhammad Abbas, Wolfgang Richter, and Sean Hu
Affiliations: Dophen Biomed and TUBE Pharmaceuticals GmbH
This poster was presented at World ADC Summit 2014 San Diego
Poster Views: 4,079
Submitted on 28 Oct 2014
Author(s): Lisha Allen, Yi Mi, Muhammad Abbas, Wolfgang Richter, and Sean Hu
Affiliations: Dophen Biomed and TUBE Pharmaceuticals GmbH
This poster was presented at World ADC Summit 2014 San Diego
Poster Views: 4,079
Abstract: Using engineered microbial transglutaminase (mTGase), we are able to conjugate any given toxin with an amine group to any mAB without the need of antibody re-engineering. Such a simple and quick site-specific conjugation method has enabled us to screen out endosome escaping & non-cleavable (EENC) linkers. These EENC linkers need an optimal length to achieve the highest ADC activity. ADCs made with EENC linkers are highly stable in human, rat and mouse plasma and potent. When two different payload toxins were conjugated site-specifically to one mAB molecule, the homogeneous hybrid ADC (DAR 2) prepared shows synergy towards tumor cell killing while mixtures of the respective two homogeneous ADCs (DAR 2) bearing the same toxins do not. The pM Ic50 in assay and high in-vivo potency challenges the widely accepted ADC concept of an activation pathway via lysosomal destruction to release free toxin. On the contrary, our data imply that ADC can be directly active after escaping from an endosome and as a result of multiple interactions of the different payloads, make the new ADCs more potent.Summary: We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Related Posters
Development of QSP model of COVID-19 based on Immune Response Template
Veronika Musatova, Oleg Demin, Maria Kupriyanova, Anna Viktorenko
Teste HPV por auto-colheita - uma alternativa ao método convencional?
Maria Beatriz Morgado; Helena Manso; Inês Pirra; Pedro Pacheco
Comparison of Caco-2 with Other Cell-based Models
Hannah Cole
Conocimientos Actitudes y Prácticas de drogas ilícitas en estudiantes de medicina en un hospital universitario de Santo Domingo
Juan Diego Perez De Los Santos
A brief introduction to non-IgG antibody
Candy Swift